|
1
|
Huang YC, Lu HI, Huang SC, Hsu CC, Chiu
NT, Wang YM, Chiu YC and Li SH: FDG PET using SUVmax for
preoperative T-staging of esophageal squamous cell carcinoma with
and without neoadjuvant chemoradiotherapy. BMC Med Imaging.
17(1)2017.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Yang H, Liu H, Chen Y, Zhu C, Fang W, Yu
Z, Mao W, Xiang J, Han Y, Chen Z, et al: Neoadjuvant
chemoradiotherapy followed by surgery versus surgery alone for
locally advanced squamous cell carcinoma of the esophagus
(NEOCRTEC5010): A phase III multicenter, randomized, open-label
clinical trial. J Clin Oncol. 36:2796–2803. 2018.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Sewnaik A, Keereweer S, Al-Mamgani A,
Baatenburg De Jong RJ, Wieringa MH, Meeuwis CA and Kerrebijn JDF:
High complication risk of salvage surgery after chemoradiation
failures. Acta Otolaryngol. 132:96–100. 2012.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Vellayappan BA, Soon YY, Ku GY, Leong CN,
Lu JJ and Tey JC: Chemoradiotherapy versus chemoradiotherapy plus
surgery for esophageal cancer. Cochrane Database Syst Rev.
8(CD010511)2017.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Paidpally V, Chirindel A, Lam S, Agrawal
N, Quon H and Subramaniam RM: FDG-PET/CT imaging biomarkers in head
and neck squamous cell carcinoma. Imaging Med. 4:633–647.
2012.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Brown C, Howes B, Jamieson GG,
Bartholomeusz D, Zingg U, Sullivan TR and Thompson SK: Accuracy of
PET-CT in predicting survival in patients with esophageal cancer.
World J Surg. 36:1089–1095. 2012.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Suzuki H, Kato K, Nishio M, Tamaki T,
Fujimoto Y, Hiramatsu M, Hanai N, Kodaira T, Itoh Y, Naganawa S, et
al: FDG-PET/CT predicts survival and lung metastasis of
hypopharyngeal cancer in a multi-institutional retrospective study.
Ann Nucl Med. 31:514–520. 2017.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Dong M, Liu J, Sun X and Xing L:
Prognositc significance of SUVmax on pretreatment
18F-FDG PET/CT in early-stage non-small cell lung cancer
treated with stereotactic body radiotherapy: A meta-analysis. J Med
Imaging Radiat Oncol. 61:652–659. 2017.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Grivennikov SI, Greten FR and Karin M:
Immunity, inflammation, and cancer. Cell. 140:883–899.
2010.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Pepys MB and Hirschfield GM: C-reactive
protein: A critical update. J Clin Invest. 111:1805–1812.
2003.PubMed/NCBI View
Article : Google Scholar
|
|
11
|
Erlinger TP, Platz EA, Rifai N and
Helzlsouer KJ: C-reactive protein and the risk of incident
colorectal cancer. JAMA. 291:585–590. 2004.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Wang CY, Hsieh MJ, Chiu YC, Li SH, Huang
HW, Fang FM and Huang YJ: Higher serum C-reactive protein
concentration and hypoalbuminemia are poor prognostic indicators in
patients with esophageal cancer undergoing radiotherapy. Radiother
Oncol. 92:270–275. 2009.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Huang W, Wu L, Liu X, Long H, Rong T and
Ma G: Preoperative serum C-reactive protein levels and
postoperative survival in patients with esophageal squamous cell
carcinoma: A propensity score matching analysis. J Cardiothorac
Surg. 14(167)2019.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Jurisic V, Terzic T, Colic S and Jurisic
M: The concentration of TNF-alpha correlate with number of
inflammatory cells and degree of vascularization in radicular
cysts. Oral Dis. 14:600–605. 2008.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Jurisic V: Multiomic analysis of cytokines
in immuno-oncology. Expert Rev Proteomics. 17:663–674.
2020.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Chen HH, Wang HM, Fan KH, Lin CY, Yen TC,
Liao CT, Chen IH, Kang CJ and Huang SF: Pre-treatment levels of
C-reactive protein and squamous cell carcinoma antigen for
predicting the aggressiveness of pharyngolaryngeal carcinoma. PLoS
One. 8(e55327)2013.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Scheller J, Chalaris A, Schmidt-Arras D
and Rose-John S: The pro- and anti-inflammatory properties of the
cytokine interleukin-6. Biochim Biophys Acta. 1813:878–888.
2011.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Liao CT, Wang HM, Chang JT, Lin CY, Ng SH,
Huang SF, Chen IH, Hsueh C, Lee LY, Lin CH, et al: Influence of
pathological nodal status and maximal standardized uptake value of
the primary tumor and regional lymph nodes on treatment plans in
patients with advanced oral cavity squamous cell carcinoma. Int J
Radiat Oncol Biol Phys. 77:421–429. 2010.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Van Westreenen HL, Plukker JT, Cobben DC,
Verhoogt CJ, Groen H and Jager PL: Prognostic value of the
standardized uptake value in esophageal cancer. Am J Roentgenol.
185:436–440. 2005.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Shum WY, Ding HJ, Liang JA, Yen KY, Chen
SW and Kao CH: Use of pretreatment metabolic tumor volumes on
PET-CT to predict the survival of patients with squamous cell
carcinoma of esophagus treated by curative surgery. Anticancer Res.
32:4163–4168. 2012.PubMed/NCBI
|
|
21
|
Higuchi K, Komori S, Tanabe S, Katada C,
Azuma M, Ishiyama H, Sasaki T, Ishido K, Katada N, Hayakawa K, et
al: Definitive chemoradiation therapy with docetaxel, cisplatin,
and 5-fluorouracil (DCF-R) in advanced esophageal cancer: A phase 2
trial (KDOG 0501-P2). Int J Radiat Oncol Biol Phys. 89:872–879.
2014.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Tamaki Y, Hieda Y, Nakajima M, Kitajima K,
Yoshida R, Yoshizako T, Ue A, Tokudo M, Hirahara N, Moriyama I, et
al: Concurrent chemoradiotherapy with docetaxel, cisplatin, and
5-fluorouracil improves survival of patients with advanced
esophageal cancer compared with conventional concurrent
chemoradiotherapy with cisplatin and 5-fluorouracil. J Cancer.
9:2765–2772. 2018.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Yamashita H, Haga A, Takenaka R, Kiritoshi
T, Okuma K, Ohtomo K and Nakagawa K: Efficacy and feasibility of
ambulatory treatment-based monthly nedaplatin plus S-1 in
definitive or salvage concurrent chemoradiotherapy for early,
advanced, and relapsed esophageal cancer. Radiat Oncol.
11(4)2016.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Yamashita H, Omori M, Takenaka R, Okuma K,
Kobayashi R, Ohtomo K and Nakagawa K: Involved-field irradiation
concurrently combined with nedaplatin/5-fluorouracil for inoperable
esophageal cancer on basis of 18FDG-PET scans: A phase II study.
Radiother Oncol. 113:182–187. 2014.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Yamashita H, Takenaka R, Omori M, Imae T,
Okuma K, Ohtomo K and Nakagawa K: Involved-field radiotherapy
(IFRT) versus elective nodal irradiation (ENI) in combination with
concurrent chemotherapy for 239 esophageal cancers: A single
institutional retrospective study. Radiat Oncol.
10(171)2015.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Minsky BD, Pajak TF, Ginsberg RJ, Pisansky
TM, Martenson J, Komaki R, Okawara G, Rosenthal SA and Kelsen DP:
INT 0123 (radiation therapy oncology group 94-05) phase III trial
of combined-modality therapy for esophageal cancer: High-dose
versus standard-dose radiation therapy. J Clin Oncol. 20:1167–1174.
2002.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Cohen C, Tessier W, Gronnier C, Renaud F,
Pasquer A, Théreaux J, Gagnière J, Meunier B, Collet D, Piessen G,
et al: Salvage surgery for esophageal cancer: How to improve
outcomes? Ann Surg Oncol. 25:1277–1286. 2018.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Sugimura K, Miyata H, Shinno N, Ushigome
H, Asukai K, Hara H, Hasegawa S, Yamada D, Yamamoto K, Haraguchi N,
et al: Prognostic impact of postoperative complications following
salvage esophagectomy for esophageal cancer after definitive
chemoradiotherapy. Oncology. 98:280–288. 2020.PubMed/NCBI View Article : Google Scholar
|
